Pathological angiogenesis is one of the major symptoms of severe ocular diseases, including corneal neovascularization. treating corneal neovascularization. In this study, we aimed to investigate whether nanoparticle-based delivery of apatinib, a selective inhibitor of vascular endothelial growth factor(VEGF) receptor 2, inhibits VEGF-mediated angiogenesis. In a rat model of alkali burn injury-induced corneal neovascularization, a subconjunctival injection of apatinib-loaded HSA-PEG (Apa-HSA-PEG) nanoparticles decreases in neovascularization compared to free apatinib solution. These in vitro and in vivo results demonstrate that apatinib-loaded nanoparticles may be promising for the prevention and treatment of corneal neovascularization-related ocular disorders.